Molly A. McGlynn

CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases

Ronald P. Gladue, Laurie Tylaska, William H. Brissette et al. · Journal of Biological Chemistry · 2003 · 89 citations · Full text

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity

Daniel P. Walker, Michael P. Zawistoski, Molly A. McGlynn et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 86 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Signal Transduction +11

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation

Daniel P. Walker, F. Christopher Bi, Amit S. Kalgutkar et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 51 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +9

Novel CCR1 antagonists with improved metabolic stability

Matthew F. Brown, M P Avery, William H. Brissette et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 33 citations · Full text

Biochemistry, Functional Selectivity, Medicine +5

Piperazinyl CCR1 antagonists—optimization of human liver microsome stability

Matthew F. Brown, Kevin B. Bahnck, Laura C. Blumberg et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 13 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +9